Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
